Integrative genomic analysis of the human response to glucocorticoids

National Institute Of Arthritis And Musculoskeletal And Skin Diseases

Investigators

Linked publications, trials & patents

Abstract

Below is a summary of the key scientific contributions made by our laboratory over the past year: 1. Neutrophils are a key target of glucocorticoids: During the past two year, we have studied the response of human and rhesus macaque neutrophils to glucocorticoids. Through an in vivo study in which we administered the glucocorticoid methylprednisolone to a group of 20 healthy volunteers, then sampled individual immune cells serially from peripheral blood, we were able to study the transcriptional response to glucocorticoids in highly pure neutrophils. Surprisingly, neutrophils appear to be the most transcriptionally responsive cell type to glucocorticoid administration. A series of follow-up in vitro and in vivo studies have revealed the molecular basis for this strong transcriptional response. In addition, we have continued to work research collaboration involving six laboratories across four NIH institutes, to perform live-tracking of rhesus macaque neutrophils by PET-CT imaging and in vivo flow cytometry, before and after glucocorticoid administration. These experiments are allowing us to study the effects of glucocorticoids on neutrophil migration, and to contribute to long-standing questions regarding neutrophil kinetics. 2. Development of a platform for the identification of compounds that mimic the immune-relevant actions of glucocorticoids: Our work on the genomic effects of glucocorticoids in human primary cells is identifying previously unrecognized actions of this class of drugs that are likely to be important for their clinical effects. One of the long-term goals of this work is to identify compounds with a more targeted range of actions and fewer side effects which can mimic the immune-relevant actions of glucocorticoids in specific disease states. In collaboration with Gianluca Pegoraro (NCI) and Iain Fraser (NIAID), we have developed a high-throughput screening method that could eventually be used for this purpose. Unlike existing methodologies, our platform uses single-molecule RNA FISH to provide single-cell targeted gene expression data and can be used in primary cells. Over the past year, we have advanced a Research Collaborative Agreement with the National Center for Advancing Translational Research (NCATS) to test its utility in a drug-discovery program. Two manuscripts describing this method have been published over the past year.